Amino Acids

, Volume 42, Issue 2–3, pp 775–781 | Cite as

Protective effects of agmatine in rotenone-induced damage of human SH-SY5Y neuroblastoma cells: Fourier transform infrared spectroscopy analysis in a model of Parkinson’s disease

  • Salvatore Condello
  • Emanuele Calabrò
  • Daniela Caccamo
  • Monica Currò
  • Nadia Ferlazzo
  • Joseph Satriano
  • Salvatore Magazù
  • Riccardo Ientile
Original Article


Agmatine is a novel neuromodulator that plays a protective role in the CNS in several models of cellular damage. However, the mechanisms involved in these protective effects in neurodegenerative diseases are poorly understood. Fourier transform infrared (FTIR) spectroscopy analysis detects biomolecular changes in disordered cells and tissues. In this report, we utilize FTIR spectroscopy to characterize the changes in rotenone-induced damage in neuronal-like differentiated SH-SY5Y neuroblastoma cells in the presence or absence of agmatine. The analysis of the FTIR spectra demonstrates significant alterations in rotenone-treated cells, whereas the FTIR spectra obtained after pre-incubation with agmatine (250 nM) significantly reduces these redox alterations and more closely resembles those of the control cells. In particular, rotenone-damaged cells demonstrate spectral alterations related to amide I, which correspond to an increase in β-sheet components, and decreases in the amide II absorption intensity, suggesting a loss of N–H bending and C–N stretching. These alterations were also evident by Fourier self-deconvolution analysis. Thus, rotenone-induced increases in the levels of stretching vibration band related to the protein carboxyl group would account for a significant amount of misfolded proteins in the cell. Agmatine effectively reduces these effects of rotenone on protein structure. In conclusion, antioxidant and scavenging properties of agmatine reduce rotenone-produced cellular damage at the level of protein structure. These, together with other previous observations, demonstrate the therapeutic potential of agmatine in the treatment of Parkinson’s disease.


Agmatine Fourier transform infrared spectroscopy SH-SY5Y neuroblastoma cells Reactive oxygen species Membrane mitochondrial potential Neuroprotection 



Fourier transform infrared


Nuclear factor κB


Parkinson’s disease


Reactive oxygen species


Mitochondrial membrane potential




Fourier self-deconvolution


Attenuated total reflection; asymmetric stretching vibration


Unprotonated carboxyl group


Symmetric unprotonated carboxyl group


  1. Agostinelli E, Marques MP, Calheiros R, Gil FP, Tempera G, Viceconte N, Battaglia V, Grancara S, Toninello A (2010) Polyamines: fundamental characters in chemistry and biology. Amino Acids 38:393–403PubMedCrossRefGoogle Scholar
  2. Ahn SK, Hong S, Park YM, Lee WT, Park KA, Lee JE (2011) Effects of agmatine on hypoxic microglia and activity of nitric oxide synthase. Brain Res 1373:48–54PubMedCrossRefGoogle Scholar
  3. Arndt MA, Battaglia V, Parisi E et al (2009) The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis. Am J Physiol Cell Physiol 296:C1411–C1419PubMedCrossRefGoogle Scholar
  4. Barth A (2000) The infrared absorption of amino acid side chains. Prog Biophys Mol Biol 74:141–173PubMedCrossRefGoogle Scholar
  5. Battaglia V, Grancara S, Satriano J, Saccoccio S, Agostinelli E, Toninello A (2010) Agmatine prevents the Ca(2+)-dependent induction of permeability transition in rat brain mitochondria. Amino Acids 38:431–437PubMedCrossRefGoogle Scholar
  6. Ben-Shachar D, Riederer P, Youdim MB (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neurochem 57:1609–1614PubMedCrossRefGoogle Scholar
  7. Calabrò E, Magazù S (2010) Inspections of mobile phone microwaves effects on proteins secondary structure by means of Fourier transform infrared spectroscopy. J Electromag Anal Appl 2:607–617CrossRefGoogle Scholar
  8. Clark J, Clore EL, Zheng K, Adame A, Masliah E, Simon DK (2010) Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One 5(8):e12333PubMedCrossRefGoogle Scholar
  9. Condello S, Currò M, Ferlazzo N, Caccamo D, Satriano J, Ientile R (2011) Agmatine effects on mitochondrial membrane potential and NF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. J Neurochem 116:67–75PubMedCrossRefGoogle Scholar
  10. Cuervo AM, Wong ES, Martinez-Vicente M (2010) Protein degradation, aggregation, and misfolding. Mov Disord 25:S49–S54PubMedCrossRefGoogle Scholar
  11. Di Giambattista L, Grimaldi P, Gaudenzi S, Pozzi D, Grandi M, Morrone S, Silvestri I, Congiu Castellano A (2010) UVB radiation induced effects on cells studied by FTIR spectroscopy. Eur Biophys J 39:929–934PubMedCrossRefGoogle Scholar
  12. Fabian H, Vogel HJ (2002) Fourier transform infrared spectroscopy of calcium-binding proteins. Methods Mol Biol 173:57–74PubMedGoogle Scholar
  13. Fabian H, Schultz C, Naumann D, Landt O, Hahn U, Saenger WJ (1993) Secondary structure and temperature-induced unfolding and refolding of ribonuclease T1 in aqueous solution. Mol Biol 232:967–981CrossRefGoogle Scholar
  14. Galloway PG, Mulvihill P, Perry G (1992) Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 140:809–822PubMedGoogle Scholar
  15. Giasson BI, Lee VM (2001) Parkin and the molecular pathways of Parkinson’s disease. Neuron 31:885–888PubMedCrossRefGoogle Scholar
  16. Gilad GM, Gilad VH, Finberg JP, Rabey JM (2005) Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem Res 30:713–719PubMedCrossRefGoogle Scholar
  17. Higgins DS, Greenamyre JT (1996) [H-3]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. J Neurosci 16:3807–3816PubMedGoogle Scholar
  18. Hong S, Lee JE, Kim CY, Seong GJ (2007) Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line. BMC Neurosci 8:81PubMedCrossRefGoogle Scholar
  19. Iizuka Y, Hong S, Kim CY, Kim SK, Seong GJ (2008) Agmatine pretreatment protects retinal ganglion cells (RGC-5 cell line) from oxidative stress in vitro. Biocell 32:245–250PubMedGoogle Scholar
  20. Ismail AA, Mantch HH, Wong PTT (1992) Aggregation of chymotrypsinogen: portrait by infrared spectroscopy. Biochim Biophys Acta 1121:183–188PubMedCrossRefGoogle Scholar
  21. Jackson M, Mantsch HH (1995) The use and misuse of FTIR spectroscopy in the determination of protein structure. Crit Rev Biochem Mol Biol 30:95–120PubMedCrossRefGoogle Scholar
  22. Kang SY, Wasaka T, Shamim EA, Auh S, Ueki Y, Lopez GJ, Kida T, Jin SH, Dang N, Hallett M (2010) Characteristics of the sequence effect in Parkinson’s disease. Mov Disord 25:2148–2155PubMedCrossRefGoogle Scholar
  23. Kim HY, Chung JM, Chung K (2008) Increased production of mitochondrial superoxide in the spinal cord induces pain behaviors in mice: the effect of mitochondrial electron transport complex inhibitors. Neurosci Lett 447:87–91PubMedCrossRefGoogle Scholar
  24. Kong J, Yu S (2007) Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim Biophys Sin 39:549–559PubMedCrossRefGoogle Scholar
  25. Lefevre T, Subirade M (2000) Molecular differences in the formation and structure of fine-stranded and particulate β-lactoglobulin gels. Biopolymers 54:578–586PubMedCrossRefGoogle Scholar
  26. Marshall LE, Himes RH (1978) Rotenone inhibition of tubulin self-assembly. Biochim Biophys Acta 543:590–594PubMedCrossRefGoogle Scholar
  27. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163:1450–1455PubMedCrossRefGoogle Scholar
  28. Morley JF, Hurtig HI (2010) Current understanding and management of Parkinson disease: five new things. Neurology 75:S9–S15PubMedCrossRefGoogle Scholar
  29. Ren Y, Zhao J, Feng J (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23:3316–3324PubMedGoogle Scholar
  30. Roberts JC, Grocholski BM, Kitto KF, Fairbanks CA (2005) Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J Pharmacol Exp Ther 314:1226–1233PubMedCrossRefGoogle Scholar
  31. Schapira AH (2006) Etiology of Parkinson’s disease. Neurology 66:S10–S23PubMedGoogle Scholar
  32. Smith BM, Franzen S (2002) Single-pass attenuated total reflection Fourier transform infrared spectroscopy for the analysis of proteins in H2O. Sol Anal Chem 74:4076–4080CrossRefGoogle Scholar
  33. Surewicz WK, Mantsch HH (1988) New insight into protein secondary structure from resolution-enhanced infrared spectra. Biochim Biophys Acta 952:115–130PubMedCrossRefGoogle Scholar
  34. Xie HR, Hu LS, Li GY (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. Chin Med J (Engl) 123:1086–1092Google Scholar
  35. Zhang G, Moore DJ, Flach CR, Mendelsohn R (2007) Vibrational microscopy and imaging of skin: from single cells to intact tissue. Anal Bioanal Chem 387:1591–1599PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Salvatore Condello
    • 1
  • Emanuele Calabrò
    • 2
  • Daniela Caccamo
    • 1
  • Monica Currò
    • 1
  • Nadia Ferlazzo
    • 1
  • Joseph Satriano
    • 3
  • Salvatore Magazù
    • 2
  • Riccardo Ientile
    • 1
  1. 1.Department of Biochemical, Physiological and Nutritional SciencesPoliclinico Universitario “G. Martino”MessinaItaly
  2. 2.Department of PhysicsUniversity of MessinaMessinaItaly
  3. 3.Department of MedicineUniversity of California, San Diego, and Veterans Administration San Diego Healthcare SystemLa JollaUSA

Personalised recommendations